and small Biotechs that claim billions in unknown future revenue will get large damage rewards.
Sentiment: Strong Sell
He joined FDA in 1999 as the Director of the Division of Oncology Drug Products and was named Director of the Office of Oncology Drug Products in April 2005., Gee Who was President in 1999, let me think.
Also if the SC is backing the Chancery, again what is taking so long for that and why the oral arguments. I believe court stalling more than SIGA.
A) Sorry, I do not see the Uniqueness of this case.
B) SIGA would negotiate a licence for ST-246 in good faith based on the LATS (same May 2013 decision ruled that SIGA negotiated in bad faith). Yes the LATS where it says non binding, thus the court predicting a company's future.
C) Bankruptcy proceedings not a factor for Delaware court.
The question is "what is the Hold Up with this case".
as you correctly stated they found the LATS binding, so why take so long with a case that's already on paper and binding.
My answer, its not so binding and requires them to get in the prediction buisness.
I am a Siganite, I disagree, the decision should be soon, everything else has been ruled on already by them they are just deciding on the specultive decision of the expectation damages.
Again I am no lawyer, but this is how I see it. The court does not want to rule on this and hoped SIGA / PIP would settle because "There was no signed Deal". SIGA was found to negotiate in bad faith. That is why the damages should limited and nowhere near 200 Million. That is why the lawyer said it would not be a case in half the states again no pharma deal, but if there were a signed deal then this would be simple case in PIPs favor.
SIGA Attorney argued expectation damages are to speculitive and don't follow current law, said this is not even a case in half of the states.. The PIP attorney argued case is unique, court IMO does not wan't to rule on this but SIGA is forcing them too. Court does seem to favor PIP but will be making new law if they favor PIP. I am not a lawyer